Elsevier Launches European Journal of Cancer iPad Edition
EJC App now available on the App Store
Oxford, September 26, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of the iPad edition of the European Journal of Cancer (EJC). Starting with the September 2011 issue, all 18 annual issues of theEJC will be available through the EJC App on the App Store. iPad editions feature the same high quality articles that are published in the print as well as online editions.
The EJC App includes published content from the highly popular EJC News and EJC News Focus, and offers readers the ability to customize the journal by selecting articles, tables, or figures to store and use later, as well as making notes on articles.
“We are proud that the EJC is the first European oncology journal to launch an iPad edition,” said Alexander Eggermont, Editor-in-Chief of the EJC. “It is important for our readers to have access to the journal whenever they need it. The iPad editions deliver theEJC to them in an easy to use format, straight to their device.”
The EJC App offers unprecedented portability to its readers, who can download the edition wirelessly. It is then available for reading and browsing offline, at times and in places where web access is not available. Of perhaps most significance, the journal can be read the same way on iPad as in print. The reader can flip pages forward and backward in the horizontal plane and scroll down vertically to read an individual article.
The EJC App is available for free from the App Store.
# # #
About the European Journal of Cancer
The EJC, with an Impact Factor of 4.944, is an international multidisciplinary oncology journal that publishes original research, editorial comments, review articles and news on basic and preclinical research, clinical oncology (medical, paediatric, radiation, surgical), translational oncology, and on cancer epidemiology and prevention. Led by Editor-in-Chief, Alexander Eggermont, the EJCis the official journal of the EORTC (the European Organisation for Research and Treatment of Cancer, ECCO (the European CanCer Organisation), the EACR (European Association for Cancer Research), and EUSOMA (the European Society of Breast Cancer Specialists).
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Senior Manager Corporate Relations, Elsevier
+31 20 485 27 36